pharmaphorum April 26, 2024
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of breath-based diagnostic solutions to improve outcomes in the developing world.
The funding represents the first time the Gates Foundation has taken an equity position in a breath diagnostics company, and is comprised of a $5 million equity investment to advance Owlstone’s Breath Biopsy platform, with $1.5 million in grant funding to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV, exploring a path by which breath-based testing could be deployed for rapid screening and earlier diagnosis.
Owlstone Medical is a global leader in Breath Biopsy for application in early disease detection...
Today's Sponsors
Today's Sponsor